BRG1

BRG1
Name	BRG1
Alternative names	Brahma-related gene 1; SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin, subfamily A, member 4
Organism	Human
Uniprot	P51531
Length	1,647 aa (human)
Family	SWI/SNF ATP-dependent chromatin remodelers

BRG1 is a central ATPase subunit of the mammalian SWI/SNF chromatin-remodeling complex that uses energy from ATP hydrolysis to reposition nucleosomes and regulate transcription. It integrates signals from transcription factors and signaling pathways to modulate chromatin accessibility during development, differentiation, and cellular responses to stress. Loss, mutation, or altered regulation of this ATPase is implicated in multiple syndromes and cancers, motivating efforts to characterize its structure, interactors, and therapeutic potential.

Introduction

BRG1 encodes an ATP-dependent helicase/ATPase that functions within multisubunit chromatin-remodeling machines related to the yeast SWI/SNF complexes. The gene SMARCA4 is conserved across metazoans with homologs in Drosophila melanogaster and Saccharomyces cerevisiae and is studied alongside paralogous subunits such as SMARCA2. BRG1-containing complexes are recruited by lineage-determining transcription factors including members of the MYC family, TP53, NF-κB, and GATA3 to regulate enhancers and promoters in processes studied by labs at institutions such as National Institutes of Health and Broad Institute.

Structure and biochemical function

The protein contains a central DExx/Helicase ATPase domain and a C-terminal bromodomain that recognizes acetylated lysines; these domains are structurally related to helicases from the SWI2/SNF2 family. High-resolution cryo-EM and X-ray crystallography studies from groups at Max Planck Society and Harvard University revealed domain arrangements and nucleotide-bound conformations. BRG1 ATP hydrolysis drives nucleosome sliding and eviction in cooperation with actin-related proteins and core subunits such as ARID1A, BAF155, and BAF170, altering chromatin landscapes mapped by techniques developed at Cold Spring Harbor Laboratory and EMBL.

Regulation and interaction partners

BRG1 activity is regulated by post-translational modifications (phosphorylation by kinases like CDK2, ubiquitination by E3 ligases such as MDM2, and acetylation by histone acetyltransferases like EP300). It interacts with transcription factors including TP63, ESR1, FOXA1, and RUNX1 and with chromatin modifiers such as HDAC1, EZH2, and components of the mediator complex studied at University of California, San Francisco. BRG1 incorporation into alternative BAF assemblies is directed by subunits encoded by genes implicated in neurodevelopmental disorders such as SMARCB1 and SMARCE1.

Role in development and differentiation

Genetic studies and conditional knockout mouse models from Jackson Laboratory and developmental genetics groups show BRG1 is essential for embryogenesis, stem cell pluripotency, and lineage commitment in tissues including neural crest, heart, and lung. BRG1 collaborates with master regulators like OCT4, SOX2, and NANOG in embryonic stem cells and with tissue-specific factors such as MyoD in myogenesis and PPARG in adipogenesis. Mutations affecting BRG1-containing complexes underlie congenital syndromes investigated in clinics at Children's Hospital of Philadelphia and Great Ormond Street Hospital.

Involvement in cancer and disease

Somatic and germline mutations of SMARCA4 are recurrent in cancers such as lung adenocarcinoma, small cell carcinoma of the ovary hypercalcemic type (SCCOHT), pancreatic cancer, and medulloblastoma; these observations have been reported by consortia including The Cancer Genome Atlas and ICGC. BRG1 loss produces synthetic lethal dependencies with paralog SMARCA2 and with factors in chromatin and DNA repair pathways involving PARP1 and ATR, informing therapeutic strategies studied at MD Anderson Cancer Center and Dana-Farber Cancer Institute. Germline variants contribute to familial cancer predisposition syndromes recognized by American College of Medical Genetics and Genomics guidelines.

Research tools and models

Key tools include CRISPR/Cas9 knockout and knock-in cell lines developed in laboratories at MIT and Stanford University, conditional Smarca4 floxed mice from repositories such as European Mouse Mutant Archive, and biochemical reconstitution of BAF complexes by structural groups at Max Planck Institute. Assays such as ATAC-seq, ChIP-seq, CUT&RUN, and Hi-C applied with computational pipelines from Broad Institute enable mapping of BRG1-dependent regulatory elements. Patient-derived xenografts and organoid systems from cancer centers like Memorial Sloan Kettering Cancer Center provide platforms for functional and drug-response studies.

Therapeutic targeting and clinical implications

Therapeutic efforts exploit vulnerabilities in BRG1-deficient tumors via synthetic lethality with SMARCA2 inhibition, inhibitors of chromatin-associated factors (bromodomain inhibitors, HDAC inhibitors), and DNA damage response modulators such as PARP inhibitors. Early-phase clinical trials and preclinical studies coordinated by centers including NCI and pharmaceutical companies like Novartis and AstraZeneca are evaluating targeted agents and combination regimens. Biomarker-driven patient selection using genomic profiling from clinical laboratories at Mayo Clinic and Sanger Institute is critical for translating BRG1 biology into precision oncology.

Category:Chromatin remodeling proteins Category:Human proteins